NMDA receptor antagonist (active drug)
Phase 2Small molecule
NMDA receptor antagonist (active drug) is one of 33 small molecule programs targeting Borderline personality disorder. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Borderline Personality Disorder
#DrugCompanyPhaseTrials
1Celexa
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tylenol
KKenvue Brands
Approved
Omacor
AstraZenecaApproved
Revia
TevaPhase 3
Zyprexa
MMODAG GmbH
Phase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Topamax
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TThe Alfred